Add this topic to your myFT Digest for news straight to your inbox
Continent’s drugmakers need to pay up to attract and retain talent, says Pascal Soriot
Judge to decide on admission of evidence as part of litigation that has knocked billions off pharma group’s value
Swiss pharma group has jettisoned 16 drugs that ‘don’t have the promise to be transformative medicines’
Pfizer’s Emblaveo to be aimed at some of the most dangerous drug-resistant bacteria
Ochre Bio partnering with Germany’s Boehringer Ingelheim on treatments that will harness the organ’s capacity to regenerate
Moderna alleges Pfizer and BioNTech infringed its patents in use of mRNA platform
Factory inspectors refuse to visit country over fears they could fall foul of tightened rules
Report from Nuffield Trust health think-tank highlights impact of leaving EU on medicine supply chains
Michel Demaré in FT hits out at ISS and Glass Lewis for applying ‘double standards’ after they opposed CEO pay package
Almost 36 per cent of shareholders voted against a £1.8mn rise for the pharma group’s boss
WuXi AppTec and WuXi Biologics under threat from proposed national security legislation
Xylazine, commonly used to sedate animals, found cut with heroin, counterfeit tablets and cannabis vapes, study finds
GQG Partners argues that pharma group has performed strongly under long-serving chief
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
Novo Nordisk and Eli Lilly, plus a clutch of rivals, aim to cut side effects while treating obesity-linked diseases
Shareholder advisory groups say potential £18.7mn payout is excessive
Record shortages of common drugs have countries scrambling for alternatives while patients skip treatments
Danish group seeks to branch out from diabetes and weight loss drugs with Cardior acquisition
Funding needed to drive innovation and make therapies available to all, says co-discoverer Jennifer Doudna
Ruth McKernan aims to make country a hub for research into the condition and accelerate development of new drugs
Acquisition gives pharmaceutical group mid-stage asset to challenge Novartis in new form of cancer care
Drugmaker releases promising trial results for a pill and expects to enter China this year
Nice fails to approve Enhertu due to value-for-money concerns despite it being recommended in Scotland
US group hunts for outsourcers to lift production of Zepbound as it takes on Danish group’s Wegovy blockbuster
GHO Capital has put contract research group FairJourney Biologics up for sale
International Edition